Clinical Trials

Sangamo announces UK authorisation of a phase 1/2 clinical trial evaluating the CAR-Treg cell therapy TX200 for kidney transplantation

Sangamo Therapeutics, a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy.

The Medicines Company announces that the ORION-10 study of inclisiran showed durable and potent lowering of LDL-C

The Medicines Company announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA (small-interfering RNA) class.

GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome

GlaxoSmithKline (GSK) said that its respiratory drug Nucala (mepolizumab) has succeeded in reducing flares in patients with hypereosinophilic syndrome (HES) in a phase 3 study.

Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure

Boehringer Ingelheim and Eli Lilly have commenced first ever trial to evaluate Jardiance (empagliflozin) in people hospitalised for acute heart failure who have been stabilised.

Roche’s risdiplam meets primary endpoint in phase 3 SMA trial

Roche said that part 2 of the SUNFISH trial assessing risdiplam for the treatment of Type 2 or 3 spinal muscular atrophy (SMA) in people aged 2-25 years has met its primary endpoint.

Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in phase III OLYMPUS and ROCKIES trials

AstraZeneca today presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased hemoglobin (Hb) levels in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) patients with anemia from chronic kidney disease (CKD), respectively.

Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years

Takeda Pharmaceutical announced that results from the primary endpoint analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate (TAK-003) were published in the New England Journal of Medicine.

Axcella achieves initial milestones with its hematology product candidate AXA4010

Axcella Health, a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, announced key milestones in the development of AXA4010, the company’s first investigational hematology product candidate.

Halozyme’s PEGPH20 pancreas cancer drug candidate fails in HALO-301 trial

Halozyme Therapeutics has discontinued the development of PEGylated recombinant human hyaluronidase (PEGPH20) after the investigational drug failed to meet the primary endpoint in a phase 3 trial in metastatic pancreas cancer.